ASCO 2025: Key Takeaways for Clinical-Stage Biopharma Innovators

Written by: Adam Callahan, Vice President, Clinical Development, Oncology & Hematology

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held from May 30^th to June 3^rd in Chicago, showcased pivotal advancements poised to reshape oncology drug development. For Biopharma Innovators, the event highlighted the ongoing trend in immunotherapy, targeted therapies, the push for precision medicine, and AI-driven diagnostics. With so much to take in from ASCO, we have created a summary of the most important themes for companies navigating the evolving oncology landscape.

Immunotherapy: Expanding Frontiers

Immunotherapy remained a central theme at ASCO 2025, with data supporting its integration into earlier treatment lines and combination regimens.(biopharmadive.com)

• Imfinzi (durvalumab): AstraZeneca’s PD-L1 inhibitor, when combined with chemotherapy before and after surgery, reduced the risk of recurrence or progression by 29% in early-stage gastric and gastroesophageal junction cancers, achieving a 67.4% event-free survival rate at 24 months. (labiotech.eu)
• Keytruda (pembrolizumab): Merck’s PD-1 inhibitor demonstrated a doubling in the time to recurrence over five years and a significant reduction in metastatic spread when administered perioperatively in head and neck cancer. (labiotech.eu)
• Versamune HPV: PDS Biotech’s immunotherapy, combined with Keytruda, showed a 50% 30-month survival rate in HPV-positive head and neck cancer patients, prompting an ongoing Phase III trial. (labiotech.eu)

Antibody-Drug Conjugates (ADCs): Redefining Standards

ADCs continue to gain prominence with data suggesting their potential to become first-line therapies in various cancers. Additional research is ongoing to understand side effects and to support moving from second-line therapy to first-line.(pfizer.com)

• Sacituzumab govitecan + pembrolizumab: The ASCENT-04/KEYNOTE-D19 Phase III trial revealed that this combination outperformed the standard of care in PD-L1 positive triple-negative breast cancer, offering prolonged progression-free survival. (oncology-central.com)
• Enhertu (trastuzumab deruxtecan) + pertuzumab: In the DESTINY-Breast09 trial, this duo extended median progression-free survival to 40.7 months in first-line HER2-positive breast cancer, compared to 26.9 months with standard therapy. (cromospharma.com)

Precision Medicine: Biomarkers and AI Integration

Advancements in biomarker identification and artificial intelligence (AI) are enhancing patient stratification and treatment personalization.

• AI in HER2 Classification: An international study demonstrated that AI tools improved pathologist concordance in HER2 classification from 66.7% to 88.5%, facilitating better identification of candidates for HER2-targeted therapies. (cromospharma.com)
• ctDNA for Minimal Residual Disease (MRD): A prospective study in resected stage II–III colon cancer showed that ctDNA-positive patients benefited from adjuvant chemotherapy, while ctDNA-negative patients had a 92% three-year disease-free survival rate without additional therapy. (cromospharma.com)

Novel Therapeutics and Combinations

Emerging therapies and novel combinations of immunotherapies are showing promise in hard-to-treat cancers.

• Inavolisib + palbociclib + fulvestrant: The INAVO120 trial reported a seven-month overall survival benefit in PIK3CA-mutated HR+/HER2- advanced breast cancer, with a 33% reduction in the risk of death. (cromospharma.com)
• Lurbinectedin + atezolizumab: The IMforte trial highlighted improved long-term survival in extensive-stage small cell lung cancer patients receiving this maintenance therapy combination. (oncology-central.com)
• GLP-1 Receptor Agonists: A large U.S.-based study indicated that these agents, commonly used for diabetes, may reduce the incidence of obesity-related cancers, notably a 28% reduction in rectal cancer. (cromospharma.com)

Clinical Trial Design: Embracing Complexity

ASCO 2025 underscored the need for more nuanced clinical trial designs that account for patient heterogeneity and long-term outcomes.

• Surrogate Endpoints vs. Overall Survival: A meta-analysis of approximately 800 Phase III oncology trials revealed that only 14.6% of studies using progression-free survival or objective response rate as primary endpoints subsequently demonstrated a statistically significant overall survival benefit. (cromospharma.com)
• Dose Optimization: Innovative designs are being proposed to optimize dosing by integrating pharmacokinetic data and patient characteristics, aiming to identify optimal doses for specific subpopulations. (arxiv.org)

Strategic Implications for Sponsors

For biopharma innovators, the insights from ASCO 2025 suggest several strategic considerations:

1. Early Integration of Biomarkers: Incorporate biomarker strategies into your targeted product profile and clinical development plans to enhance patient selection and trial efficiency.
2. Adoption of Advanced Technologies like AI: Consider how you can leverage AI for diagnostic precision, and incorporating advanced technologies that empower streamlined the clinical trial processes.(diaceutics.com)
3. Flexible Trial Designs: Design trials that take emerging data into account, including the use of co-primary endpoints and adaptive dosing strategies. Ensure that you are working with a CRO that is familiar with adaptive trial designs to bring flexibility to your process.
4. Focus on Combination Therapies: Explore synergistic combinations, particularly those involving immunotherapies, novel combinations, and targeted agents.

Given the complexity and speed of change, there’s never been a more important time to work with a CRO partner that combines deep therapeutic expertise and operational excellence that powers agility. At Caidya, our integrated medical, scientific, and operational teams know how to navigate critical inflection points across the oncology and hematology development lifecycle. Our structure and culture enable fast, flexible solutions built around your needs. With access to senior leadership, empowered teams, and the expertise and willingness to be flexible we operate at the speed of your innovation.

1. eu. (2025, June 4). ASCO 2025: Key highlights in cancer therapeutics. Retrieved from https://www.labiotech.eu/trends-news/asco-2025-key-highlights-cancer-therapeutics/?utm_source=chatgpt.com
2. Oncology Central. (2025, June 3). ASCO 2025 guide: Breaking news and key themes. Retrieved from https://www.oncology-central.com/asco-2025-guide-breaking-news-and-key-themes/?utm_source=chatgpt.com
3. Cromos Pharma. (2025, June 2). ASCO 2025 Oncology Sponsor Guide: New Data, Breakthroughs and Insights. Retrieved from https://cromospharma.com/asco-2025-oncology-sponsor-guide/?utm_source=chatgpt.com
4. Montazerhodjat, V., Hu, J., Wang, X., & Lo, A. (2025). Dose optimization in clinical trials: Incorporating PK variability and patient covariates to improve target attainment. arXiv preprint arXiv:2504.14622. Retrieved from https://arxiv.org/abs/2504.14622?utm_source=chatgpt.com